Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study

R. McCrery*, F. Lane, K. Benson, C. Taylor, O. Padron, B. Blok, S. De Wachter, A. Pezzella, J. Gruenenfelder, M. Pakzad, M.A. Perrouin-Verbe, L. Le Normand, P. Van Kerrebroeck, J. Mange, K. Peters, M. Kennelly, A. Shapiro, U. Lee, C. Comiter, M. MuellerH.B. Goldman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

PURPOSE: Sacral neuromodulation is a guideline recommended treatment of urinary dysfunction and fecal incontinence in patients in whom conservative treatments have failed. Historically sacral neuromodulation has been delivered using a nonrechargeable device with an average life span of 4.4 years. Surgery is required to replace the implanted neurostimulator due to battery depletion. Implantation of a long-lived implanted neurostimulator can eliminate the need for replacement surgeries, potentially reducing patient surgical risks and health care costs. The Axonics r-SNM System™ is a miniaturized, rechargeable sacral neuromodulation system designed to deliver therapy for at least 15 years. The ARTISAN-SNM (Axonics® Sacral Neuromodulation System for Urinary Urgency Incontinence Treatment) study is a pivotal study using rechargeable sacral neuromodulation therapy to treat urinary urgency incontinence. Six-month results are presented. MATERIALS AND METHODS: A total of 129 eligible patients with urinary urgency incontinence were treated. All participants were implanted with a tined lead and the rechargeable sacral neuromodulation system in a nonstaged procedure. Efficacy data were collected using a 3-day bladder diary, the validated ICIQ-OABqol (International Consultation on Incontinence Questionnaire Overactive Bladder quality of life) questionnaire and a participant satisfaction questionnaire. Therapy responders were identified as participants with a 50% or greater reduction in urinary urgency incontinence episodes compared to baseline. We performed an as-treated analysis in all implanted participants. RESULTS: At 6 months 90% of participants were therapy responders. The mean ± SE number of urinary urgency incontinence episodes per day was reduced from 5.6 ± 0.3 at baseline to 1.3 ± 0.2. Participants experienced a clinically meaningful 34-point improvement on the ICIQ-OABqol questionnaire. There were no serious device related adverse events. CONCLUSIONS: The Axonics r-SNM System is safe and effective with 90% of participants experiencing clinically and statistically significant improvements in urinary urgency incontinence symptoms.

Original languageEnglish
Pages (from-to)185-192
Number of pages7
JournalJournal of Urology
Volume203
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • constant-current
  • deep brain-stimulation
  • implantable neurostimulators
  • multicenter
  • overactive
  • patient reported outcome measures
  • quality of life
  • sacral neuromodulation system
  • symptoms
  • therapy
  • urge
  • urinary bladder
  • urinary incontinence
  • MULTICENTER
  • SYMPTOMS
  • SACRAL NEUROMODULATION SYSTEM
  • THERAPY
  • DEEP BRAIN-STIMULATION
  • CONSTANT-CURRENT

Cite this